Claims
- 1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified A-chain peptide or functional analog thereof, in an amount effective to ameliorate a neurological disorder, the amino acid sequence of the peptide comprising SEQ ID NO:1 or the sequence with conservative amino acid substitutions.
- 2. The pharmaceutical composition of claim 1, wherein the neurological disorder is a memory disorder.
- 3. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is a carrier formulated for intranasal, intraperitoneal, intracerebroventricular, intradermal, intramuscular, intravenous, or subcutaneous delivery.
- 4. The pharmaceutical composition of claim 1, wherein the carrier is formulated for intranasal delivery.
- 5. A method for ameliorating a memory disorder in a subject, comprising administering to a subject a therapeutically effective amount of an A-chain peptide or functional analog thereof.
- 6. The method of claim 5, wherein the administration of a therapeutically effective amount of an A-chain peptide or functional analog thereof increases memory retention in the subject.
- 7. The method of claim 5, wherein the administration of a therapeutically effective amount of an A-chain peptide or functional analog thereof enhances associative learning in the subject.
- 8. The method of claim 5, wherein the administration of a therapeutically effective amount of an A-chain peptide or functional analog thereof modulates activity of a tyrosine kinase coupled receptor.
- 9. A method of ameliorating a neurological disorder in a subject comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an A-chain peptide or functional analog thereof, such that the A-chain peptide or functional analog thereof modulates activity of a tyrosine kinase coupled receptor.
- 10. The method of claim 9, wherein the neurological disorder is a memory disorder.
- 11. The method of claim 9, wherein the step of administering the pharmaceutical composition is intranasal.
- 12. The method of claim 9, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier formulated for intranasal delivery.
- 13. The method of claim 12, wherein the pharmaceutical composition further comprises cyclodextrin.
PRIORITY
[0001] The present invention claims priority to U.S. Provisional Application No. 60/378,318 filed May 6, 2002, entitled “Insulin-Associated Peptides For Cerebral Health.”
Provisional Applications (1)
|
Number |
Date |
Country |
|
60378318 |
May 2002 |
US |